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ABSTRACT 
O@ective: To investigate the a determinant of hepatitis B virus 
(HBV) S gene for the presence of mutations responsible for 
vaccine failure. 
Methods: The a determinant of HBV S gene was amplified in 
sera obtained from 11 HBV-positive infants and children born 
to asymptomatic HBeAg-positive mothers by nested poly- 
merase chain reaction (PCR) and subsequently subjected to 
direct sequencing. The sequences obtained were translated 
into the corresponding amino acids and compared to amino 
acid sequences of HBV subtype adr. All infants under investi- 
gation had received recombinant hepatitis B vaccine within 
24 hours after delivery and had completed the recommended 
vaccination course, consisting of three to four doses adminis- 
tered at defined intervals. 
Results: The usual divergence regarding genotype and sub- 
type was identified among the 11 samples tested. Only two 
exhibited a point mutation within the a determinant, one of 
which consisted of a substitution of glycine with alanine at posi- 
tion 145, and the other of a substitution of glutamine with argi- 
nine at position 129. 
Conclusion: Eleven neonates were positive for HBV infection, 
and two of them showed point mutations that might have ren- 
dered the virus resistant to the vaccine, possibly due to a 
change in the S protein’s secondary structure. Yet, this remains 
a matter of speculation, since the other seven cases positive 
for hepatitis B viral DNA merely demonstrated the usual geno- 
type and subtype. The presence of escape mutants of HBV can 
be considered rather negligible with respect to vaccination pro- 
grams, especially as the vaccine has been shown to reduce 
hepatitis B, as well as hepatocellular carcinoma efficiently. 
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The recombinant hepatitis B vaccine has been proven to 
be highly effective. It is the frost vaccine capable of reduc- 
ing the incidence of hepatocellular carcin0ma.l Its intro- 
duction has opened the way toward controlling this often 
fatal viral infection of global proportions and thus toward 
diminishing the number of people afflicted with hepato- 
cellular carcinoma. In Thailand, an area of high endemic- 
ity, inclusion of the vaccine into the national vaccination 
program represented a crucial step in advancing the goal 
of finally eradicating the disease.2,3 
The vaccine has proven highly efficacious in pro- 
tecting high-risk neonates, that is, children of asympto- 
matic carrier mothers. However, there have been rare 
reports of children who were infected after having com- 
pleted the full vaccination course. Two different mecha- 
nisms were postulated as the cause of this failure: (1) 
intrauterine infection4s5 or (2) a mutation rendering the 
virus capable of escaping the immune reaction triggered 
by the vaccine.6 
Hepatitis B virus replicates by reverse transcriptase, 
which lacks proofreading capacity, thereby leading to a 
higher number of mutations in the HBV genome than is 
common for DNA viruses.’ Some of the resulting variants 
may exhibit a replication advantage and become domi- 
nant. Thereupon, forces, such as the humoral or cellular 
immune response, can positively select some so-called 
escape mutants from the pool of variants with similar 
replication potential8 Studies performed on the evolu- 
tion of viruses under antibody pressure have shown that 
adding neutralizing antibodies to virus cultures regularly 
causes the emergence of isolates not neutralized by the 
added antibodies, especially upon application of mono- 
clonal reagents in which the change in viral antigenic 
structure required to avoid neutralization involves the 
loss of a single epitope.” 
An additional target of HBV for the humoral immune 
response is represented by the a determinant predom- 
inantly located between amino acids 121 and 149 of 
the hepatitis B surface antigen (HBsAg). Since a large 
Hepatitis B Virus in Vaccine Failure / Poovorawan et al 217 
proportion of the anti-HBs expressed in immune serum 
is directed against this determinant, especially the “sec- 
ond loop” between amino acids 139 and 147,lO muta- 
tions either in the determinant itself or in its vicinity are 
selected in patients having received active and passive 
vaccination against HBV1’-16 
The purpose of the present study was to examine 
children of HBV carrier mothers, who had been vacci- 
nated immediately after birth, for the presence of the 
nucleotide sequence coding for HBsAg by means of 
nested polymerase chain reaction (PCR),17 to determine 
the frequency of such postexposure prophylaxis failures 
and to subsequently elucidate the type of mutation 
encountered by direct sequencing. 
PATIENTS AND METHODS 
Patients 
At the Viral Hepatitis Research Unit, Department of Pedi- 
atrics, Faculty of Medicine, Chulalongkorn University Hos- 
pital, Bangkok, Thailand, sera were obtained1 from 11 
infants and children between 2 months and 10 years of 
age (4 girls and 7 boys). All of them had been born to 
asymptomatic HBV carrier mothers positive for HBeAg 
and had been infected with hepatitis B virus despite hav- 
ing received the complete course of vaccination, includ- 
ing a first dose that was administered within 24 hours 
after birth. Five of the children had simultaneously 
received HB immunoglobulin (Ig). After having obtained 
informed consent from their parents, blood samples were 
taken from the children during follow-up examinations at 
the outpatient clinic, and the sera were stored at -70°C 
until further analysis. 
Serologic Tests 
Tests for HBsAg and HBeAg were performed using com- 
mercially available kits (Abbott Laboratories, North 
Chicago, IL). 
Hepatitis B Virus DNA Detection 
The selection of primer sets for hepatitis B virus DNA 
amplification was based on sequence data provided by 
Dr. M.Yano at the World Health Organization (WHO) Col- 
laboration Center, Nagasaki, Japan. 
Hepatitis B virus DNA was amplified by nested PCR 
in an automated thermocycler (Perkin Elmer Cetus, 
Branchville, NJ) as described elsewhere.” To ccwer the a 
determinant of the HBV S gene completely, two1 separate 
amplification reactions were performed employing two 
different sets of primer pairs (Bio-Synthesis, Lewisville, 
TX). The primer sequences and their respective 
nucleotide numbers were as follows: outer primers: F4, 
5’GTC CTC CAA TIT GTC C’TG G-3’ (nucleotide 348-366); 
R5, 5’-AGC CCA AAA GAC CC4 CAA TTC-3’ (nucleotide 
1015-995); inner primers: S2-1, 5’-CAA GGT ATG TTG 
CCC GTT TG-3’ (nucleotide 455-474); Sl-2,5’-CGA ACC 
ACT GAA CAA ATG GC-3’ (nucleotide 704-684). 
Regarding the reactions performed, 5 PL of the 
respective DNA sample were added to a reaction mix- 
ture containing 1 U of Tdq polymerase (Perkin Elmer 
Cetus), each of four deoxynucleotide triphosphates 
(Pi-omega, Madison, WI) at a concentration of 200 PM, the 
primer pair required for the first amplification round, and 
the primer pair required for the second amplification 
round, respectively, each individual primer at a 1 FM con- 
centration, 10 mM Tris buffer and 1.5 mM MgCI, at a final 
volume of 50 ~.LL. The first amplification round consisted 
of one cycle at 94°C 55°C and 72°C for 1 minute each, 
followed by 30 cycles comprising a 30-second denatura- 
tion step at 94°C a 30-second annealing step at 55°C 
and a 30-second extension step at 72°C each. The ampli- 
fication was concluded by one cycle at 94°C for 1 minute, 
55°C for 2 minutes, and 72°C for 10 minutes. For the sec- 
ond amplification round 5 PL of the first PCR product 
were added to the reaction mixture and amplification 
was performed in a manner identical to the first round. 
Then, 10 PL of each amplified DNA sample were loaded 
on a 2% NuSieve (FMC BioProducts, Rockland, ME) 
agarose gel stained with ethidium bromide on prepara- 
tion. Electrophoresis was performed at 120 V for 45 min- 
utes, and the product band specific for each individual 
test, that is 250 base-pairs (bp), was visualized on an ultra- 
violet light box. 
DNA Purification and Sequencing 
The PCR product was purified for sequencing, using the 
QIAquick PCR Puritication Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s specifications, and sub- 
sequently subjected to 2% agarose gel electrophoresis to 
ascertain its purity 
For determining the concentration of the amplified 
DNA, the absorption was measured at 260 nm of every 
sample in an ultraviolet spectrophotometer (Shimadzu 
UV I60 A, Tokyo, Japan). The concentration was calcu- 
lated according to the formula, 1 ODzGo = 50 kg double- 
stranded DNA. Between 10 and 30 ng/yL (3-6 FL) of 
every respective DNA were subjected to cycle sequenc- 
ing using dye-labelled terminators (8 p,L and 3.2 pM of 
specific primer at a final reaction volume of 20 p,L), which 
represents a rapid and convenient method for perform- 
ing enzymatic extension reactions for subsequent DNA 
sequencing on the ABI Prism 310 genetic analyzer (Perkin 
Elmer Cetus). This round of amplifications was performed 
according to the manufacturer’s specifications, using the 
inner forward primer employed in each individual test to 
amplify the particular DNA strand of interest for further 
sequencing. Cycle sequencing consisted of 25 cycles at 
96°C for 10 seconds (denaturation), 50°C for 5 seconds 
(annealing), and 60°C for 4 minutes (extension). The reac- 
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tion was concluded by cooling the thermal ramp to 4°C. 
The extension products were subsequently purified from 
excess unincorporated dye terminators by ethanol pre- 
cipitation, according to the manufacturer’s specifications 
(Perkin Elmer Cetus), and subsequently prepared for load- 
ing on the ABI Prism 310 genetic analyzer. 
For all the subsequent steps, the authors referred to 
the ABI Prism 310 genetic analyzer user’s manual (Perkin 
Elmer Cetus). All sequences thus obtained were con- 
firmed by performing the cycle sequencing once more 
with the inner reverse primers. 
The nucleotide sequences obtained were translated 
into the corresponding amino acid sequences, according 
to the universally valid genetic code, and compared with 
the a determinant (amino acids 110-170) of the a& strain 
sequence pN~~260. l8 The amino acid sequences were dis- 
tinguished based on the classification by Norder et a1.18,19 
RESULTS 
All 11 neonates received the first dose of vaccine within 
24 hours after delivery: four were given the subsequent 
doses according to the 0-, l-, 2-, and la-month schedule, 
and seven according to the 0-, l-, and 6-month schedule, 
respectively. Five of the 11 infants had received HBIg 
along with the first dose of vaccine. Of the 11 neonates, 
one (P-2001) developed the clinical symptoms typical for 
acute hepatitis B at the age of 8 months and subsequently 
“recovered” in such a way that he became a chronic 
asymptomatic carrier. Another case (P-2004) advanced to 
acute liver failure at 6 months of age, which resulted in 
cirrhosis. Yet, this child completely cleared HBV at the 
age of 2 years. The remaining nine infants have been and 
are to this day asymptomatic HBV carriers. The details 
regarding HBsAg in infants and children are shown in 
Table 1. 
Five cases were identified of identical genotype and 
subtype as the sequence derived from the reference strain 
pN~R260,‘* that is, genotype C, subtype adr. One of those 
five (143-113 1) showed a substitution of glyciue with ala- 
nine at position 145, thus expressing a point mutation, 
which possibly caused vaccine failure. Two cases were of 
genotype Bl, subtype adw2, with threonine instead of 
isoleucine at position 126, threonine instead of serine at 
position 143, and lysine instead of arginine at position 
160. One of those had a substitution of glutamine with 
arginine at position 129, which might lead to antibody fail- 
ure as a consequence of altered secondary structure of 
the antigenic epitope. The remaining four cases belonged 
to genotype A, subtype adw2, characterized by a substi- 
tution of isoleucine with threonine at position 126, of 
threonine with asparagine at position 13 1, of serine with 
threonine at position 143, and of arginine with lysine at 
position 160 (Table 2). 
DISCUSSION 
The World Health Organization has devised a strategy 
aimed for the global elimination of new cases of hepati- 
tis B.** To that end, WHO called for the addition of HBV 
to the six existing vaccines in the expanded program on 
immunization (EPI) in all countries by the year 1997.2’ In 
1989, the Thailand Ministry of Public Health (MOPH) 
established a pilot project for HB immunization in two 
provinces, Chonburi and Chiangmai. The aims of the pro- 
ject were (1) to develop strategies for the integration of 
HB immunization into the EPI schedule with acceptable 
vaccine coverage and immunogenicity, (2) to identify 
obstacles in the delivery of the first dose of HB vaccine 
in the first week of life, and (3) to refine methods for 
increasing community awareness and acceptance of the 
national immunization program. As a result of this effort, 
the incidence of HBsAg positivity in the children dropped 
from 5.4% in 1988 to 0.8% in 1993, and incidence of anti- 
HBs seropositivity increased from 2.4% to 70%.3 
Table 1. Serologic Data for Infants with Vaccine Failure Born to HBeAg-Positive Mothers 
Vaccination HBsAg 
Patient Schedule 
Number fmo) HBlg Month Year 
0 1 2 4 6 9 12 2 3 4 5 
P-150 0, 1,2,12 - - + + + ND + + + + + + 
P-134 0, 1,2,12 - + + + + ND + + + + + 
P-553 0, 1,2, 12 
t 
- - - - ND & t + + + 
P-1056 0, 1, 6 - - ND + c + + + + + 
P-1096 0,1,6 - - - + 
P-1101 0,1,6 - - - - ND - + + + + 
P-l 131 0, 1, 6 - - - ND - + t + N’D + + 
P-2001 0, 1, 6 + ND ND ND ND ND 
P-2002 0,1,2,12 + ND ND ND ND ND I& 
+ 
+ 
P-2003 0, 1, 6 + ND ND ND ND ND ND + N’D t -F + 
P-2004 0, 1, 6 t ND ND ND ND t + + 
ND = not done, + = positive, - = negative. 
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Table 2. Amino Acid Sequence of the Antigenic Epitope of the HBV S Gene Amplified in Patients’ Sera 
Patient 
Number 170 120 130 140 150 760 170 
pNDR260 
P-150 
P-134 
P-553 
P-l 056 
P-l 096 
P-1101 
P-l 131 
P-2001 
P-2002 
P-2003 
P-2004 
LPGmSTG PCKTCTIPAQ GTSMFPSCCC TKPSDGNCTCIP IPSSWAFA RFLWEWASVR F 
I s T KY 
I-s- ~- 
-2 
T -N -T KY 
I-s- ~- 
I s T R 
I-S- 
___- 
IN 
--I- KY 
T KY 
ISS ~- 
-T 
I s A 
IS- T 
ISS ~- 
-N T- KY 
T KY ~- -N -T 
I s .-^ 
The most significant advance toward the goal of 
worldwide elimination of HBV will come with increases 
in the number of persons vaccinated. In additi’on, efforts 
are needed to improve vaccine efficacy and to decrease 
the vaccine failure rate. The authors conducted a follow- 
up of up to 96 months after administration of recombi- 
nant hepatitis B vaccine to neonates of HBsAg- and 
HBeAg-positive mothers. This study revealed a vaccine 
failure rate of 1.5% in infants who also received immuno- 
globulin and of 5% in infants who did not receive im- 
munoglobulin.2~22 These cases of mother-to-child 
transmission of HBV despite vaccination may be attrib- 
utable to intrauterine infection, exposure to high virus 
titers during labor, inadequate prophylactic procedures, 
or the existence of vaccine escape mutants.23 
The group of Okamoto and other recent findings 
support the thesis of ongoing, yet restricted immune sur- 
veillance of HBV envelope proteins in chronic carriers, 
thereby providing selective pressure for the elmergence 
of HBV escape mutants. I* The majority of these mutants 
had a point mutation from guanosine to adenosine at 
nucleotide position 587, which results in an ammo acid 
substitution of glycine with arginine in the highly anti- 
genie a determinant of HBsAg, eliminating the anti- 
genicity of some but not all a epitopes.‘* Additional single 
amino acid substitutions in the a determinant of HBV S 
gene less frequently encountered but also associated with 
antibody escape include, among others, a substitution of 
either isoleucine or threonine with asparagine or serine 
at position 126, a substitution of threonine with1 serine at 
position 140, and a substitution of aspartic acid. with ala- 
nine at position 144.23 Moreover, Okamoto et al discov- 
ered a 24-bp insertion leading to an eight-amino acid 
insertion at codon 123 of the HBV S gene in one patient 
seronegative for HBsAg but reactive for HBeAg.l* The 
finding of in-frame deletion mutants in the preS1 and 
preS2 genes isolated from 6 HBV carriers and from 7 of 
14 HBV patients with conventional HBV serologic profiles 
devoid of S-gene mutations was also reported.‘* 
CONCLUSIONS 
The results of the present study show a substitution of 
glycine with alanine, that is, from an amino acid with an 
uncharged polar side chain to one with a nonpolar side 
chain, at position 145 in 1 of the 11 sera tested and 
another case expressing a substitution of glutamine with 
arginine, that is from an amino acid with an uncharged 
polar side chain to one with a basic side chain, at posi- 
tion 129. In other words, 11 neonates were positive for 
HBV infection and two of them showed point mutations 
that might have rendered the virus resistant to the vac- 
cine, possibly due to a change in the S protein’s secondary 
structure.Yet, this remains a matter of speculation, since 
the other seven cases positive for hepatitis B viral DNA 
merely demonstrated the usual genotype and subtype 
variability That is, some neonates born to asymptomatic 
HBV-carrier mothers had contracted HBV infection 
despite vaccination with the recombinant HB vaccine 
within the first 24 hours after delivery. Although the virus 
strains prevalent in Thailand belong to subtype ad, in 
five cases genotype C, subtype adr was detected, in six 
cases subtype adw2 was detected, with four of the cases 
belonging to genotype A, and two to genotype Bl , respec- 
tively. This does not compromise the efficacy of the 
ay-subtype-specific vaccine in use, since it is first and 
foremost the a determinant that constitutes the antigenic 
epitope. Nevertheless, in the infants investigated in the 
course of the present study the infection probably 
occurred in utero, particularly since in Thailand, vertical 
hepatitis B virus transmission has been found to occur 
more frequently than horizontal transmission. Conse- 
quently, the incubation period of hepatitis B virus had 
been brought to conclusion before either active or pas- 
sive immunoprophylaxis could be administered, thereby 
rendering it inefficient. Alternatively, administration of 
the immunoprophylaxis could have led to a prolonged 
incubation period of the virus in those cases in which the 
infants had contracted HBV during the delivery process 
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so that only after 9 or even 12 months, as in cases P-l 131 
and P-1101 (see Table l), they became HBsAg positive. 
Finally, those infants whose infection became evident at 
the age of 6 or 12 months might have contracted HBV 
horizontally as a result of vaccine failure.Yet, its molecu- 
lar basis remains obscure, especially since the only two 
point mutations detected in the present study after direct 
sequencing of the a determinant have as yet not been 
identified by any research group as the cause of reported 
antibody escape. On the other hand, Tai et al reported the 
identification of a point mutation identical to the one 
found in this study as regards position (aa 129) and amino 
acid substitution (glutamine is changed into arginine) in 
13.9% of hepatocellular carcinoma patients.25 
Data from this study indicate that the presence of 
vaccine escape mutants can be considered rather negli- 
gible with respect to vaccination programs. The policy 
devised by WHO to include HB vaccine, either alone or 
together with HBIg, into the EPI has proven highly effi- 
cient in reducing HBV infection and consequently, the 
incidence of cirrhosis and hepatocellular carcinoma can 
be expected to decrease in the near future. 
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